Press Releases Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-01-17 pm EST			5-day change	1st Jan Change
147.03 ^USD	-0.50%		+1.77%	+1.67%

Jan. 20	Sumitomo Pharma Co., Ltd. Announces Agreement on Co-Promotion Collaboration Partner for Marketing of Pplat Xeplion and Xeplion Trial in Japan with Johnson & Johnson	CI
Jan. 17	S&P 500 Logs 2.9% Weekly Gain on Easing Inflationary Pressures, Strong Bank Earnings	MT

Press Releases

RYBREVANT® plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer	Jan. 16	AQ
New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer	Jan. 15	PR
J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders	Jan. 13	AQ
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.	Jan. 13	BU
Johnson & Johnson : MedTech Announces CE Mark Approval for Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter	Jan. 10	PU
Johnson & Johnson - Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis	Jan. 10	AQ
Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis	Jan. 09	PR
Johnson & Johnson - RYBREVANT plus LAZCLUZE shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib	Jan. 08	AQ
Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease	Jan. 08	PR
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2025	Jan. 02	BU
Johnson & Johnson - European Commission approves RYBREVANT in combination with LAZCLUZE for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer	Dec. 31	AQ
Johnson & Johnson to license novel oral assets, further strengthening commitment to atopic dermatitis	Dec. 27	AQ
Applied Therapeutics Appoints John H. Johnson as Executive Chairman	Dec. 23	AQ
Johnson & Johnson Participates in the Inauguration of World Health Organization (WHO) Academy to Improve Training and Education of Health Workers Globally	Dec. 18	AQ
Johnson & Johnson Participates in the Inauguration of World Health Organization Academy to Improve Training and Education of Health Workers Globally	Dec. 18	AQ
Johnson & Johnson : submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA® (ibrutinib) in adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplant	Dec. 18	PU
Johnson & Johnson submits application seeking U.S. FDA approval of SIMPONI for the treatment of pediatric ulcerative colitis	Dec. 17	AQ
Johnson & Johnson - Update on U.S. regulatory review of subcutaneous amivantamab	Dec. 17	AQ
Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference	Dec. 12	BU
Johnson & Johnson : U.S. FDA Expands Indication for Impella Heart Pumps to Treat Pediatric Patients	Dec. 12	PU
Johnson & Johnson : 2024 Fourth-Quarter Press Release & Supplemental Schedules	Dec. 10	PU
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results	Dec. 10	BU
Johnson & Johnson - TECVAYLI demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma	Dec. 09	AQ
Johnson & Johnson - DARZALEX FASPRO -based regimens demonstrate improved rates of minimal residual disease negativity and progression-free survival in patients with newly diagnosed multiple myeloma	Dec. 09	AQ
Johnson & Johnson : MedTech Joins Experts to Define and Classify Surgical Site Outcomes	Dec. 05	PU

Become a member to access more news.

100% Free Registration

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

J&J to Buy Intra-Cellular for About $14 Billion

January 13, 2025 at 12:32 pm EST